Researchers hunt for proteins that control age-related inflammation
New CapabilitiesGeroscience builds its toolkit of molecular targets, one protein at a time
May 19th, 2026: Inflammaging finding enters wider news cycleNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Overview
Updated May 20Chronic, low-grade inflammation builds up with age and drives many of the diseases that come with growing old. A team at the University at Buffalo says they've found a protein, tristetraprolin, that pumps the brakes on it. When they boosted the protein in older mice, the animals grew stronger and had healthier bones than untreated peers.
The finding adds a concrete molecular target to geroscience, the field trying to treat aging itself instead of the diseases it causes. If the mouse results hold up in people, future therapies could slow age-related decline across the board rather than one disease at a time.
Why it matters
If geroscience finds the right molecular brakes on inflammation, you could prevent age-related decline rather than manage it disease by disease.
Questions about this story
Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.
No questions yet — be the first to ask.
Key Indicators
Voices
Curated perspectives — historical figures and your fellow readers.
Play
Exploring all sides of a story is often best achieved with Play.
WHO SAID WHAT?
Can you match the quotes to the right people?
- points for each correct match.
- time bonus when you answer in under seconds.
- streak bonus once you hit correct in a row.
— Who said this?
Tip: press 1– to answer.
points — sign up to put that on the leaderboard.
Higher or Lower
A number from this story, against one from elsewhere in the news — guess which is bigger, then keep the chain going. 5 rounds, 3 strikes; a miss costs a strike and resets your streak.
Keyboard: ↓/L lower · ↑/H higher
0 points — sign up to put that on the leaderboard.
Timeline
Order five events from this story, oldest at top. Each in the right slot scores 1 — neighbours within one slot count too. Your previous result — green ✓ for exact slots, yellow ~ for off by one. Cards now in true chronological order.
Sign up to save your score and track a streak across stories.
Connections
Sixteen names from the news. Find the four hidden groups of four. Four mistakes max.
Sign up to keep a daily streak — a new puzzle lands every day.
Exit debate?
Your progress in this debate will be lost.
- 1 Two AI personas square off on this story.
- 2 You predict who'll win each round — correct picks earn XP.
- 3 One crossfire question is yours to fire. Pick it carefully.
Couldn't generate a topic
Select Your Champions
Choose one persona for each side of the debate
DEBATE TOPIC
Choose personas with different perspectives for a more dynamic debate.
Select debater for this side:
No debate personas available right now.
Select debater for this side:
No debate personas available right now.
Who's Got This Round?
Make your prediction before the referee scores
The referee scores both sides on
Round Results
Set the Crossfire
Pick the question both personas must answer in the final round
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
XP Breakdown
Prediction History
People Involved
Organizations Involved
Dental school whose periodontal research led into broader work on chronic inflammation and aging.
NIH institute that funds most US aging research, including senolytics, rapamycin, and inflammaging work.
Timeline
June 2000 May 2026
-
Inflammaging finding enters wider news cycle
Latest CoverageScienceDaily and other outlets amplify the TTP results, framing them as a concrete molecular target for slowing age-related decline.
-
TTP study published
PublicationAging and Disease publishes the Buffalo paper showing boosted TTP makes older mice stronger and healthier.
-
Buffalo TTP project begins
ResearchKirkwood's lab starts its six-year NIH-funded study of tristetraprolin in aging.
-
First human senolytic pilot
ClinicalA small open-label trial tests senolytic drugs in patients with idiopathic pulmonary fibrosis.
-
TAME trial proposed
Trial designNir Barzilai proposes Targeting Aging with Metformin, a US trial to test whether a generic drug can delay multiple age-related diseases.
-
Senolytics shown in mice
PreclinicalJames Kirkland's Mayo Clinic team reports that drugs clearing senescent cells improve healthspan in old mice.
-
Geroscience consensus published
Field-definingA Cell paper formalizes geroscience: target aging mechanisms, treat many diseases at once.
-
Rapamycin extends mouse lifespan
PreclinicalA Nature paper shows rapamycin, an mTOR inhibitor, lengthens life in elderly mice. Geroscience gains its first widely cited proof of concept.
-
Franceschi coins 'inflammaging'
ConceptItalian immunologist Claudio Franceschi names the chronic low-grade inflammation of aging and frames it as a shared driver of age-related disease.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
Akira Endo isolates the first statin (1976)
Japanese biochemist Akira Endo isolated compactin from a Penicillium fungus while screening for cholesterol-lowering compounds. The molecule blocked the enzyme HMG-CoA reductase and became the prototype for the statin class.
Compactin showed cholesterol-lowering effects in animals and small human studies through the early 1980s but was dropped over safety concerns.
Merck's lovastatin won FDA approval in 1987, eleven years after Endo's discovery. Statins later became one of the most prescribed drug classes in the world.
When a single molecular target really does control a chronic process, the payoff can be enormous, but rarely arrives in under a decade. TTP, if real, is at year zero of that arc.
Rapamycin extends mouse lifespan (2009)
A Nature paper from the NIH Interventions Testing Program showed rapamycin extended lifespan in elderly mice by 9 to 14 percent. The drug, originally an immunosuppressant for transplant patients, became the highest-profile longevity candidate in mainstream science.
Off-label rapamycin use spread among biohackers and a small number of physicians within five years. The PEARL trial began testing it in humans in 2020.
Rapamycin has not won an FDA aging indication. Its side effect profile and regulatory caution have kept it stuck despite consistent mouse results.
Shows the gap between strong mouse biology and accepted human therapy. TTP modulation would have to cross the same gap, which has held up rapamycin for over fifteen years.
Senolytics shown to extend mouse healthspan (2015)
James Kirkland's team at Mayo Clinic reported in Aging Cell that a combination of dasatinib and quercetin selectively killed senescent cells in old mice, improving cardiovascular function and physical performance. The paper triggered a wave of geroscience startups and human pilot studies.
Two biotechs, Unity Biotechnology and Cleara Biotech, formed within two years. The first human pilot launched in 2018 in patients with idiopathic pulmonary fibrosis.
Senolytics remain in human trials a decade later, with mixed results. No senolytic has won FDA approval for an aging indication.
Same arc as the TTP finding: clean mouse data, fast pharma interest, slow translation. Reads as the most direct template for what comes next.
